Experimental Evaluation of Gene Silencing As New Therapeutic Option in the Treatment of Gemcitabine-chemoresistant Non-small-cell Lung Cancer by Stoleriu, Mircea Gabriel et al.
 Stoleriu MG et al. American Journal of Cancer Therapy and Pharmacology 2014, 2:8-16 
  
Ivy Union Publishing | http: //www.ivyunion.org July 23, 2014 | Volume 2 | Issue 1  
Page 1 of 9 
 
 
Experimental Evaluation of Gene Silencing As 
New Therapeutic Option in the Treatment of 
Gemcitabine-chemoresistant Non-small-cell 
Lung Cancer  
 
 Mircea Gabriel Stoleriu
1
, Andrea Nolte-Karayel
1
, Julia Kurz
1
, Martin Michaelis
2
, Jindrich 
Cinatl jr.
3
, Volker Steger
1
, Hans Peter Wendel
1
, Christian Schlensak
1
, Tobias Walker
1*
 
 
1
Department of Thoracic, Cardiac and Vascular Surgery, Tuebingen University Hospital, Germany 
2
Centre for Molecular Processing and School of Biosciences, University of Kent, Canterbury, UK 
3
Institute for Medical Virology, Hospital of Goethe University, Frankfurt am Main, Germany 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Keywords: Gemcitabine; siRNA; chemoresistance; lung adenocarcinoma 
Reviewer: Jagadeesh G. Hiremath, PhD, Department of Pharmaceutics, University of Nizwa, Oman. 
Academic Editor: Xiaoning Peng, PhD, Hunan Normal University School of Medicine, China 
Received: April 10, 2014 Accepted: June 22, 2014 Published: July 23, 2014 
Competing Interests: The authors have declared that no competing interests exist. 
Copyright: 2014 Walker T et al. This is an open-access article distributed under the terms of the Creative Commons 
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author 
and source are credited. 
*Correspondence to: Tobias Walker, Department of Thoracic, Cardiac and Vascular Surgery, Tuebingen University Hospital, 
Germany.  Email: Tobias.Walker@med.uni-tuebingen.de  
 
 
 
 
Abstract: 
The evolution of technological and therapeutic applications of siRNA since the description of the interference process in 2006 
has been extremely rapid and very productive. Currently, at least ten tumor entities and ten viral infections in which 
siRNA-based therapy might play an auspicious role have been described. Because of the very poor prognosis of NSCLC, we 
examined and proposed a new therapeutic alternative for the treatment of gemcitabine-resistant lung cancer via 
siRNA-specific silencing of six important molecules involved in lung carcinogenesis. 
Methods: One hundred thousand gemcitabine-chemoresistant A549 cell lines were cultured in a humidiﬁed atmosphere 
containing 5 % CO2 at 37°C and were transfected with specific siRNA targeting HIF1, HIF2, STAT3, SRF, E2F1 and 
Survivin. The relative expression of these molecules was examined via qRT-PCR and the viability of the chemoresistant cells 
after siRNA transfection was analyzed using a CASY system 72 hours after specific transfection.  
Results: The relative expression of the examined target molecules was suppressed by up to 73 % after specific transfection, 
and the CASY system demonstrated a concentration-dependent reduction in the viability of chemoresistant A549 cells of up 
to 61 %. Therefore the obtained results were significantly better in comparison to the control group.  
Conclusions: siRNA complexes may induce accurate suppression of various target molecules involved in lung tumor growth, 
in particular in gemcitabine- chemoresistant adenocarcinoma. Therefore, siRNA-based nanotechnology might represent a 
productive platform for the development of new chemotherapeutic agents for advanced stages of lung cancer in the context of 
a personalized multimodality regimen.  
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Introduction 
The evolution of siRNA (short intereference RNA) 
based technology since the description of the 
interference process published by the two Nobel Prize 
winners (A. Z. Fire and C.C. Melo) in 2006 has been 
rapid and highly productive. Within about 7 years, 
different scientists had described at least ten systemic 
infections and more than ten tumor entities in which a 
therapeutic application of siRNA-mediated interference 
may have a beneficial role. siRNA silencing of various 
crucial molecules involved in genitourinary, 
neurological [l], hematological and cardiovascular 
diseases are currently productive platforms from which 
to identify new therapeutic options and develop new 
drugs.  
In lung carcinogenesis, current efforts concerning 
siRNA silencing processes are focusing on early 
recognition of clinical manifestations of the disease in 
order to provide an effective curative treatment. 
Unfortunately, about 40% of patients have metastasis at 
presentation [1], when most therapeutic options have 
only a palliative intent [2,3]. In order to develop an 
effective therapy, a multimodal therapeutic concept 
including chemotherapy, radiotherapy and surgery [4, 5] 
is under intensive study. According to the S3 guidelines 
for lung cancer, chemotherapeutic agents (platinum 
derivates, taxanes, vinca alkaloids or various 
monoclonal antibodies) may be used in all stages of the 
disease [6]. Indeed, the current chemotherapeutic 
regimen represents the gold standard for the treatment of 
stage IV, accounting for about 55% of patients [7, 8].  
Because chemotherapy is an important component for 
the treatment of lung cancer, the therapeutic efficiency 
of the chemotherapeutic agent as well the tumor 
response to treatment are crucial. An important factor 
that reduces the efficiency of the treatment in NSCLC 
(Non small cell lung cancer) is the development of 
multifactorial chemoresistance. Due to various 
alterations in drug metabolism and genetic alterations in 
the DNA [7,9], the chemotherapeutic regimen plays only 
a modest role in increasing the overall survival rate and 
quality of life of patients with this disease [10,11]. 
Therefore, early identification of new targets in the 
pathogenesis of lung cancer as well as the development 
of alternative strategies based on the genetic pathways of 
chemoresistance are pivotal. One of the most studied 
therapeutic alternatives in various carcinoma cell lines, 
and in particular in lung cancer, is based on 
siRNA-mediated posttranscriptional gene silencing.  
siRNAs are double-stranded RNA molecules 
containing 20-25 nucleotides, with an important role in 
innate immunity and the regulation of gene expression 
[12,13]. The most important effect of siRNA 
interference is the transient suppression of various target 
oncogenes or tumor suppressor genes, thus providing 
efficient, short-term suppression of gene expression and 
consecutively of their phenotypic effects [14].  
Given the increased chemoresistance of NSCLC cell 
lines treated with gemcitabine (72%), we proposed an 
alternative regimen for the treatment of 
gemcitabine-resistant adenocarcinoma cells via 
siRNA-mediated specific interference. Experimentally, 
we induced an individualized siRNA-mediated 
knockdown of six crucial molecules involved in lung 
carcinogenesis: HIF 1 (Hipoxia inducible factor 1), 
HIF2 (Hipoxia inducible factor 2), STAT3, SRF (Serum 
Response Factor), E2F1 and Survivin. We studied the 
relative expression of the target molecules after 
siRNA-mediated interference and measured the viability 
of the chemoresistant adenocarcinoma cells 3 days after 
specific siRNA transfection.  
Materials and Methods 
Cell culture and primary cell isolation 
One hundred thousand gemcitabine-chemoresistant 
A549 cells were cultured in a humidiﬁed atmosphere 
containing 5% CO2 at 37°C in a special high glucose 
medium (Dulbecco’s Modified Eagle Medium). The 
cultured media were supplemented with 100 U penicillin, 
20 µg streptomycin, 2 mM L-glutamine and 10% 
conditioned fetal bovine serum (PAA Laboratories, 
Cölbe, Germany). 
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  Transfection protocol of siRNAs  
One hundred thousand A549 cells were seeded 24 
hours before transfection into 12-well plates for 
qRT-PCR, along with 20,000 cells for the quantification 
of surviving cells via CASY analysis (Figure 1). The 
transfection medium was enriched with different 
concentrations of interferinTM (1.17 µl at 25 nM siRNA 
and 1.75 µl at 50 nM and 100 nM siRNA).  
 
 
 
 
  
                                      
 
 
 
 
                                 Figure 1 Study design 
 
The transfection mixture consisted of basal medium, 
interferinTM (Polyplus, Illkirch, France) and 300 µl of 
transfection medium containing siRNA. For the CASY 
experiments, 300 µl transfection medium containing 50 
nM specific siRNA was used. All reagents were 
incubated for 20 minutes at room temperature. 
Afterwards, the chemoresistant A549 cells were 
incubated with the siRNA-containing transfection 
medium for 2 hours at 37°C.  
The cells were grown in duplicate for qRT-PCR 
analysis and quadruplicate for CASY analysis. The 
studied chemoresistant cells were divided into three 
different groups:  
Group I (control group): Gemcitabine-chemoresistant 
A549 cells transfected with nonsense siRNA. According 
to the Qiagen transfection protocol (Hilden, Germany), 
the transfection reagent enables high transfection 
efficiency with low cytotoxicity. Furthermore, these 
nonsilencing siRNAs have been validated using 
Affymetrix GeneChip arrays and show only minimal 
nonspecific effects on gene expression.  
Group II (scrambled siRNA/siRNA control group): 
Gemcitabine-chemoresistant A549 cells treated with 
nonspecific siRNA provided by Qiagen. 
Group III (specific siRNA group): 
Gemcitabine-chemoresistant A549 cells transfected with 
specific siRNA targeting HIF1, HIF 2, STAT 3, SRF, 
E2F1 and Survivin.  
siRNA sequences  
The specific targets were identified using a sense and 
antisense sequence synthesized and validated by 
Eurofins MWG Operon, Ebersberg, Germany (Table 1).  
Quantitative real-time polymerase chain 
reaction (qRT-PCR) 
Two hundred nanograms of RNA extracted using the 
AurumTM total RNA mini-kit (Bio-Rad, Hercules, CA, 
USA) were reverse transcribed using an iSkriptTM 
cDNA Synthesis Kit 24 hours after transfection. The 
specific primers (Table 2) were synthesized via software 
developed by Premier Biosoft International (Eurofins 
MWG Operon, Germany). In all PCR reactions, the 
standardized mixture contained a green fluorescent 
substrate (IQTM SYBR®Green Supermix, Bio Rad, CA, 
USA), 2 ng of cDNA, and 400 nM forward and reverse 
primer.  
The level of fluorescence was used to quantify gene 
expression according to the comparative delta Ct method. 
The average value and the standard deviation were also 
determined. The GAPDH gene, which is equally 
expressed in various mammalian cells, was used as a 
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reference gene to validate the PCR reactions [15].  
 
                Table 1 The sense and antisense sequences of the targeted molecules 
Name Sequence Target gene 
E2F1 Sense: 5 G´ACGUGUCAGGACCUUCGU3  ´  
Antisense: 5  ´ACGAAGGUCCUGACACGUC3  ´  
E2F1 gene, 
Chromosome 20 (human) 
Survivin  
 
Sense: 5 G´GACCACCGCAUCUCUACA3  ´  
Antisense: 5 U´GUAGAGAUGCGGUGGUCC3  ´  
BIRC5 gene, 
Chromosome 17 (human) 
STAT3  
 
Sense: 5 G´CCUCUCUGCAGAAUUCAA3  ´  
Antisense: 5 U´UGAAUUCUGCAGAGAGGC3  ´  
STAT3 gene, 
Chromosome 17 (human) 
HIF 1A 
 
Sense: 5 A´GAGGUGGAUAUGUGUGGG3  ´  
Antisense: 5 C´CCACACAUAUCCACCUCU3  ´  
Chromosome 14, q21-q24 (human) 
HIF 2A  
 
Sense: 5 A´GAUUCCUCGUUAUUGUUG3  ´  
Antisense: 5 C´AACAAUAACGAGGAAUCU3  ´
Chromosome 2, p21-p16 (human) 
SRF  
 
Sense: 5 G´AUGGAGUUCAUCGACAACAA3  ´  
Antisense: 5 G´UUGUCGAUGAACUCCAUCUU3  ´  
Chromosome 6 (human) 
scr siRNA Not published  
 
Table 2 The forward and reverse sequences of the targeted molecules 
Name Sequence 
E2F1 forward 5’-ACCATCAGTACCTGGCCGAGAGC-3’ 
reverse 5’-ATAGCGTGACTTCTCCCCCGGG-3’ 
Survivin forward 5’-CTTTCTTGGAGGGCTGC-3’ 
reverse 5’-TGGGGTCGTCATCTGGC-3’ 
STAT 3 forward 5’-CGGAGAAACAGTTGGGACCCCT-3’ 
reverse 5’-GAGCTGCTCCAGGTACCGTGT-3’ 
HIF 1 forward 5’-TGCAGAATGCTCAGAGAAAGCGAA-3’ 
reverse 5’-GCTGCATGATCGTCTGGCTGCT-3’ 
HIF 2 forward 5’-TGTCAGGCATGGCAAGCCGG-3’ 
reverse 5’-GCACGGGCACGTTCACCTCA-3’ 
SRF forward 5’-AGTGCAGGCCATTCAAGT-3’;  
reverse 5’-ACGGATGACGTCATGATGGTG-3’; 
GAPDH forward 5’-TCAACAGCGACACCCACTCC-3’;  
reverse 5’-TGAGGTCCACCACC-CTGTTG- 3’ 
CASY cell confirmation 
The remaining cells were counted 72 hours after 
transfection using a CASY® Cell Counter (Schärfe 
System, Reutlingen, Germany). The differentiation and 
detachment of the dead cells was induced using 500 μl 
Trypsin/ Ethylenediaminetetraacetic acid and 500 μl 
Trypsin Neutralization Solution (PromoCell, Germany). 
The number of nontransfected cells was equivalent to 
100% and the number of living cells was used for 
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further calculation. 
Statistical analysis 
All data were expressed as mean ± standard error of 
mean and analyzed using one-way ANOVA with 
Bonferroni’s multiple comparison test. Special statistical 
software (GraphPad Prism, La Jolla, USA) was used. 
Experiments were carried out three times independently 
with different A549 chemoresistant cell populations and 
executed in duplicate for qRT-PCR and quadruplicate for 
CASY measurements. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2  
Relative E2F1 (A), HIF1 (B), HIF 2 (C), SRF (D), STAT 3 (E) and Survivin (F) expression of gemicitabine-resistant A549 
adenocarcinoma cells 24 hours after transfection with corresponding siRNAs. The X-axis describes the different concentrations of the 
siRNAs, whereas the Y-axis represents the relative expression of the silenced genes with untransfected cells set to one.  
 
Results  
The transfection of A549 cells with E2F1, HIF1, HIF2, 
SRF, STAT3 and Survivin in gemcitabine-resistant A549 
cell lines (Figure 2) led to a moderate reduction in gene 
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expression (33-37%, 3-9%, 35-73%, 47-69%, 38-53% 
and 53-62%, respectively).  
CASY analysis after a single shot therapy showed a 
moderate reduction in the viability of gemicitabine A549 
chemoresistant cells (cells remaining in SRF group 65%, 
Survivin group 59%, E2F1 group 48%, STAT3 group 
49%, HIF1 group 42% and HIF2 group 39%).  
The relative expression of the studied molecules was 
suppressed by up to 73% after specific transfection, and 
the CASY system demonstrated a 
concentration-dependent reduction in the chemoresistant 
A549 cells of up to 61%. Regarding the suppression of 
the target molecules and the remaining cells after 
specific transfection, the obtained results were 
significantly better in comparison to the control group.  
 
 
 
 
 
 
 
 
 
 
Figure 3 Percentage of cells 3 days after transfection with specific siRNA targeting E2F1, HIF 1, HIF 2, SRF, STAT 3 
and Survivin, compared with untransfected cells (set to 100%) in A549 cell lines treated with gemcitabine.  
Discussion 
According to the EUROCARE-4 statistics, the 5-year 
age-adjusted survival rate for patients with lung cancer 
diagnosed in 2000-2002 was very poor (10%) [16]. 
Despite extensive research on new treatment 
modalities, lung cancer remains the most common 
cancer worldwide in terms of incidence and mortality in 
both men and women. Therefore, early diagnosis, 
effective treatment and adherence to treatment are the 
most important goals in attempts to prevent the 
evolution of lung cancer to advanced stages.  
As most cases are diagnosed late, research efforts in 
the area of lung cancer are focusing not only on early 
detection, but also on new therapeutic strategies for the 
advanced stages.  
According to the S3 guidelines, the therapeutic 
regimen of lung cancer is based on a multimodal 
concept including (neo)adjuvant chemotherapy, 
radiation therapy and surgery in selected patients. 
Because chemotherapy is a useful component in the 
treatment of all stages of lung cancer, it is crucial to 
study the response of the tumor cells to different 
therapeutic agents, to analyze the multifactorial etiology 
of chemoresistance, and to suggest new therapeutic 
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strategies according to mutational analysis of the 
oncogenes or tumor suppressor genes involved in lung 
carcinogenesis.  
Recent publications demonstrated that the early 
development of chemoresistance has negative 
consequences on the effectiveness of treatment and 
consecutively on survival rate. Furthermore, the 
prevalence of in vitro chemoresistance of resected 
NSCLC has increased significantly for first-line 
chemotherapy agents [10] (cisplatin 63%, carboplatin 
68%, doxorubicin 75%) [10]. Chemoresistance has also 
reached very high levels in patients treated with 
gemcitabine (72%) [10]. Therefore, we examined a new 
alternative in the treatment of 
gemcitabine-chemoresistant adenocarcinoma cell lines 
involving siRNA-mediated interference.  
The same concept was studied by Zhang et al., who 
discussed the role of miRNAs in lung carcinogenesis, 
including potential translational clinical implementation 
[17]. Similar to the experiments performed in other 
cancer cell lines, we studied a new in vitro model for the 
treatment of gemcitabine-resistant lung cancer via 
specific siRNA silencing of six crucial molecules 
involved in lung carcinogenesis (SRF, E2F1, Survivin, 
HIF 1, HIF 2 and STAT3 ). SRF is a highly predictive 
transcription factor that suppresses cell differentiation 
and growth via the TGF-beta 1 pathway. E2F1 is a 
highly potent activator of both cell proliferation and 
p53-dependent / independent apoptosis. Survivin is a 
potent inhibitor of apoptosis via its regulation of mitosis. 
The HIF family members are potent transcription factors 
that promote neoangiogenesis in various carcinoma lines, 
in particular in lung cancer. STAT3 is a transcription 
activator that promotes oncogenesis and stimulates 
tumor suppression depending on the tumor stage in 
various carcinoma cell lines.  
We obtained for each examined molecule individual 
reliable responses in a concentration-dependent manner, 
suggesting that the concomitant suppression of these six 
molecules might be an effective method for preventing 
the development of chemoresistance through multiple 
mechanisms of action. This is another argument that 
supports the concept of individualized multimodal 
therapy in order to facilitate an effective multi-targeted 
knockdown of gemcitabine-resistant adenocarcinoma 
cells.  
We proposed a new in vitro model based on A549 
adenocarcinoma cells that are similar to adenocarcinoma 
cells in vivo. These cells grow as a monolayer and 
ensure the optimal diffusion of nutritional substances. In 
order to facilitate optimal tumor growth, the A549 cells 
were cultured on a high glucose medium supplemented 
with effective nutritional factors. We also used a special 
transient transfection protocol according to the original 
publications of Nolte et al. [18, 19] in order to facilitate 
short-term modification of the relative expression of 
targeted molecules and to minimize the toxicity to the 
neighboring healthy cells.  
In our in vitro experiments, the carcinoma cells were 
suppressed after specific siRNA transfection by up to 
61%, whereas the gene expression of the target 
molecules was suppressed by up to 73% in a 
concentration-dependent manner. This indicates that the 
selected target molecules might be predictive biomarkers 
in the treatment of gemcitabine-resistant lung 
adenocarcinoma. A similiar hypothesis was proposed by 
Ren et al., who demonstrated that the overexpression of 
RRM1 (ribonucleotide reductase M1) enhances 
resistance to gemcitabine, suggesting that the mRNA 
levels of RRM1 could be used as a biomarker in the 
individual customized therapy of NSCLC [20].  
Another study proposed a combination therapy of 
low-dose gemcitabine and specific PLK1-shRNA (Polo 
like kinase 1- short harpin RNA) in order to improve the 
efficiency of the chemotherapeutic agent against the 
carcinoma cells [21]. Unlike the aforementioned study, 
we used siRNA-mediated interference to knockdown six 
other molecules involved in lung carcinogenesis, with 
reliable and reproducible results. A recent study 
regarding the chemosensitization of lung 
adenocarcinoma cells to gemcitabine using a binding 
protein called 4Ei-1 produced promising results [22]. A 
similar hypothesis concerning HIF-siRNA mediated 
chemosensitization was proposed by Minakata et al. [23]. 
In addition, we demonstrate in our study that HIF is a 
potent target in gemcitabine-resistant NSCLC. That 
having been said, we believe that our method offers a 
platform for further research concerning the 
chemosensitization of multiresistant adenocarcinoma 
cells via siRNA-specific multi-targeted interference.  
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In order to facilitate an optimal knockdown of the 
target proteins, we conducted the CASY analysis 72 
hours after specific transfection to achieve the maximum 
efficiency possible and to enable a protective short-term 
process with less adverse effects on the body.  
As siRNA interference may only knockdown and not 
knock out the target molecules [14], we observed a 
number of surviving gemcitabine-chemoresistant cells 
(39-65%) after specific transfection, suggesting that this 
therapy might be successful in terms of a multi-shot 
transfection strategy in combination with chemotherapy, 
radiation therapy or surgery.  
Our preliminary in vitro results show similarities with 
those obtained by other groups, suggesting that 
siRNA-mediated interference might represent a 
reproducible alternative transient regimen in the 
treatment of gemcitabine-chemoresistant NSCLC as 
well an important starting point for further extensive 
research regarding new therapeutic strategies.  
Furthermore, we believe that siRNA-based 
nanotechnology might provide an accurate 
individualized tool for the chemosensitization and 
radiosensitization of (multi-) resistant lung cancer as 
well for the local transient application of siRNA 
nanoparticles during various surgical procedures with 
isolated lung perfusion. 
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